Indoco Remedies Limited (INDOCO.BO)
INR 235.05
(0.45%)
INR 235.05
(0.45%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.34 Billion INR | 64.18% |
| 2022 | 6.29 Billion INR | 8.34% |
| 2021 | 5.81 Billion INR | 6.48% |
| 2020 | 5.46 Billion INR | -7.76% |
| 2019 | 5.92 Billion INR | -0.9% |
| 2018 | 5.97 Billion INR | 6.12% |
| 2017 | 5.62 Billion INR | 3.22% |
| 2016 | 5.45 Billion INR | 49.81% |
| 2015 | 3.64 Billion INR | 24.44% |
| 2014 | 2.92 Billion INR | 7.55% |
| 2013 | 2.72 Billion INR | -1.98% |
| 2012 | 2.77 Billion INR | 2.17% |
| 2011 | 2.71 Billion INR | 27.5% |
| 2010 | 2.13 Billion INR | 25.42% |
| 2009 | 1.69 Billion INR | 23.72% |
| 2008 | 1.37 Billion INR | 0.0% |
| 2006 | 1.13 Billion INR | 5.89% |
| 2005 | 1.07 Billion INR | -1.78% |
| 2004 | 1.09 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 13 Billion INR | 217.15% |
| 2024 Q1 | -11.1 Billion INR | -207.37% |
| 2023 FY | 10.34 Billion INR | 64.18% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 8.67 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 10.34 Billion INR | 0.0% |
| 2022 FY | 6.29 Billion INR | 8.34% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 6.94 Billion INR | 0.0% |
| 2022 Q4 | 6.29 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 FY | 5.81 Billion INR | 6.48% |
| 2021 Q4 | 5.81 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 5.96 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 5.46 Billion INR | 0.0% |
| 2020 FY | 5.46 Billion INR | -7.76% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 6.51 Billion INR | 0.0% |
| 2019 Q2 | 6.43 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 5.92 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 5.92 Billion INR | -0.9% |
| 2018 FY | 5.97 Billion INR | 6.12% |
| 2018 Q4 | 5.97 Billion INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2017 FY | 5.62 Billion INR | 3.22% |
| 2016 FY | 5.45 Billion INR | 49.81% |
| 2015 FY | 3.64 Billion INR | 24.44% |
| 2014 FY | 2.92 Billion INR | 7.55% |
| 2013 FY | 2.72 Billion INR | -1.98% |
| 2012 Q4 | 2.77 Billion INR | 0.0% |
| 2012 FY | 2.77 Billion INR | 2.17% |
| 2011 FY | 2.71 Billion INR | 27.5% |
| 2010 FY | 2.13 Billion INR | 25.42% |
| 2009 FY | 1.69 Billion INR | 23.72% |
| 2008 FY | 1.37 Billion INR | 0.0% |
| 2006 FY | 1.13 Billion INR | 5.89% |
| 2005 FY | 1.07 Billion INR | -1.78% |
| 2004 FY | 1.09 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 36.448% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 93.205% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -99.624% |
| Granules India Limited | 22.95 Billion INR | 54.944% |
| Achyut Healthcare Limited | 2.01 Million INR | -513675.46% |
| Ajanta Pharma Limited | 10.71 Billion INR | 3.436% |
| Alkem Laboratories Limited | 48.6 Billion INR | 78.722% |
| Alpa Laboratories Limited | 307.12 Million INR | -3267.489% |
| Brooks Laboratories Limited | 248.6 Million INR | -4060.2% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -182.491% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -112.469% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -390.423% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 90.331% |
| Eris Lifesciences Limited | 38.26 Billion INR | 72.974% |
| FDC Limited | 3.7 Billion INR | -178.828% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 84.116% |
| Gufic Biosciences Limited | 5.59 Billion INR | -84.69% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -351.735% |
| Ipca Laboratories Limited | 33.74 Billion INR | 69.35% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -3385.072% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -247.767% |
| Lasa Supergenerics Limited | 541.92 Million INR | -1808.438% |
| Laurus Labs Limited | 42.71 Billion INR | 75.787% |
| Lupin Limited | 96.23 Billion INR | 89.253% |
| Mankind Pharma Limited | 23.87 Billion INR | 56.681% |
| Medicamen Biotech Limited | 940.36 Million INR | -999.815% |
| Medico Remedies Limited | 438.24 Million INR | -2259.941% |
| Megasoft Limited | 1.85 Billion INR | -458.095% |
| NATCO Pharma Limited | 10.53 Billion INR | 1.801% |
| Piramal Pharma Limited | 74 Billion INR | 86.025% |
| RPG Life Sciences Limited | 1.38 Billion INR | -649.333% |
| Sigachi Industries Limited | 2.53 Billion INR | -308.582% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 94.366% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -408.414% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -787.59% |
| Unichem Laboratories Limited | 8.06 Billion INR | -28.169% |
| Wanbury Limited | 3.15 Billion INR | -227.753% |
| Windlas Biotech Limited | 1.76 Billion INR | -486.731% |
| ZIM Laboratories Limited | 2.08 Billion INR | -397.044% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 85.594% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -165.671% |
| Divi's Laboratories Limited | 18.99 Billion INR | 45.538% |
| Hester Biosciences Limited | 3.59 Billion INR | -187.708% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -303.807% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -1219.467% |
| Bal Pharma Limited | 2.51 Billion INR | -311.834% |
| Strides Pharma Science Limited | 37.68 Billion INR | 72.553% |
| Venus Remedies Limited | 1.39 Billion INR | -642.555% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -25.351% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 7.807% |
| Shilpa Medicare Limited | 12.93 Billion INR | 20.028% |
| Aarti Drugs Limited | 11.5 Billion INR | 10.098% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -63.414% |
| Suven Life Sciences Limited | 148.62 Million INR | -6858.842% |
| Ind-Swift Limited | 13.45 Billion INR | 23.123% |
| Valiant Laboratories Limited | 1.05 Billion INR | -877.294% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 3.415% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 26.878% |
| Themis Medicare Limited | 1.88 Billion INR | -447.933% |
| Hikal Limited | 12.99 Billion INR | 20.413% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 87.395% |
| Sequent Scientific Limited | 8.27 Billion INR | -24.994% |
| Novartis India Limited | 1.8 Billion INR | -474.221% |
| Wockhardt Limited | 39.87 Billion INR | 74.06% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 83.121% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -3481.141% |
| Neuland Laboratories Limited | 5.49 Billion INR | -88.091% |
| Morepen Laboratories Limited | 4.45 Billion INR | -131.901% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1506.239% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -423.313% |